- Report
- March 2024
- 188 Pages
Global
From €3237EUR$3,374USD£2,788GBP
€3597EUR$3,749USD£3,098GBP
- Report
- March 2024
- 200 Pages
Global
From €3982EUR$4,150USD£3,430GBP
- Drug Pipelines
- April 2024
- 220 Pages
Global
From €2399EUR$2,500USD£2,066GBP
- Report
- October 2023
- 189 Pages
Global
From €4701EUR$4,900USD£4,049GBP
- Report
- January 2022
- 105 Pages
Global
From €4558EUR$4,750USD£3,925GBP
- Report
- October 2021
- 54 Pages
Global
From €2399EUR$2,500USD£2,066GBP
- Report
- December 2019
- 95 Pages
Global
From €3838EUR$4,000USD£3,306GBP
- Report
- February 2024
- 87 Pages
Global
From €3500EUR$3,908USD£3,120GBP
- Report
- March 2021
Japan, United States, ... Japan, United States, Europe
From €912EUR$950USD£785GBP
- Report
- February 2020
Japan, United States, ... Japan, United States, Europe
From €912EUR$950USD£785GBP
Sirolimus, also known as rapamycin, is an immunosuppressive drug used to prevent organ rejection in transplant patients. It works by inhibiting the activity of T-cells, which are responsible for attacking foreign bodies. Sirolimus is also used to treat certain types of cancer, such as lymphoma and Kaposi's sarcoma. It is often used in combination with other immunosuppressive drugs, such as cyclosporine and tacrolimus.
Sirolimus is available in both oral and intravenous formulations. It is generally well-tolerated, with the most common side effects being nausea, vomiting, and diarrhea. It is also associated with an increased risk of infection and certain types of cancer.
The sirolimus market is highly competitive, with several major players. These include Pfizer, Novartis, Merck, and Astellas. Other companies, such as Mylan and Teva, also offer generic versions of the drug. Show Less Read more